November 8, 2007
Even more benefit.
Analysis of:
Ranexa(R) Significantly Reduces Incidence Of CV Death, MI Or Recurrent Ischemia In MERLIN TIMI-36 Patients With Elevated BNP | www.medicalnewstoday.com
This analysis is solely the work of the author. It has not been edited or endorsed by GLG.
Implications: The good news gets better as there is now data from MERLIN that corroborates the news from CARISA showing a reduction in HbGA1C that was significant.
Analysis: This along with the cardiac data and the COURAGE data should give many MD's reason to re-consider this drug.
Analysis: This along with the cardiac data and the COURAGE data should give many MD's reason to re-consider this drug.
Report a Concern
More GLG News in
Healthcare
Most Popular:
Source Article | Expert Analyses
Painkiller Risk Found for Heart Patients
www.nytimes.com
FDA Asks if Pain Pill Is Tamper-Proof
online.wsj.com
Merck KGaA: Overall Survival in First-Line NSCLC Reaches 15 Months
www.pipelinereview.com
Hospitals See Drop in Paying Patients
www.nytimes.com
Gardasil, Merck's Cervical Cancer Vaccine, Demonstrated Efficacy in Preventing HPV-Related Disease in Males in Phase III Study
www.fiercebiotech.com
Is Celebrex Next ?
November 18, 2008
Will contact lens solutions cost more to ship and store?
November 13, 2008
Economy's impact on healthcare facilities
November 13, 2008
Tamper Proof Narcotic Pain pill? YES
November 13, 2008
A closer look
November 11, 2008